272 related articles for article (PubMed ID: 18785154)
1. A group center overlap based approach for "3D QSAR" studies on TIBO derivatives.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Chem; 2009 Apr; 30(6):922-33. PubMed ID: 18785154
[TBL] [Abstract][Full Text] [Related]
2. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
3. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
4. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.
Smith RH; Jorgensen WL; Tirado-Rives J; Lamb ML; Janssen PA; Michejda CJ; Kroeger Smith MB
J Med Chem; 1998 Dec; 41(26):5272-86. PubMed ID: 9857095
[TBL] [Abstract][Full Text] [Related]
5. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
6. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
[TBL] [Abstract][Full Text] [Related]
7. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
10. Anti-HIV activity of HEPT, TIBO, and cyclic urea derivatives: structure-property studies, focused combinatorial library generation, and hits selection using substructural molecular fragments method.
Solov'ev VP; Varnek A
J Chem Inf Comput Sci; 2003; 43(5):1703-19. PubMed ID: 14502505
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations.
Eriksson MA; Pitera J; Kollman PA
J Med Chem; 1999 Mar; 42(5):868-81. PubMed ID: 10072684
[TBL] [Abstract][Full Text] [Related]
12. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Mol Model; 2008 Nov; 14(11):1009-21. PubMed ID: 18642033
[TBL] [Abstract][Full Text] [Related]
13. Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors.
Marrero-Ponce Y
J Chem Inf Comput Sci; 2004; 44(6):2010-26. PubMed ID: 15554670
[TBL] [Abstract][Full Text] [Related]
14. Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives.
Darnag R; Mostapha Mazouz EL; Schmitzer A; Villemin D; Jarid A; Cherqaoui D
Eur J Med Chem; 2010 Apr; 45(4):1590-7. PubMed ID: 20110136
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Di Santo R; Costi R; Artico M; Ragno R; Lavecchia A; Novellino E; Gavuzzo E; La Torre F; Cirilli R; Cancio R; Maga G
ChemMedChem; 2006 Jan; 1(1):82-95. PubMed ID: 16892340
[TBL] [Abstract][Full Text] [Related]
16. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
[TBL] [Abstract][Full Text] [Related]
18. Towards a MIP-based alignment and docking in computer-aided drug design.
Barbany M; Gutiérrez-de-Terán H; Sanz F; Villà-Freixa J
Proteins; 2004 Aug; 56(3):585-94. PubMed ID: 15229890
[TBL] [Abstract][Full Text] [Related]
19. Quantitative structure-activity relationship studies of TIBO derivatives using support vector machines.
Darnag R; Schmitzer A; Belmiloud Y; Villemin D; Jarid A; Chait A; Mazouz E; Cherqaoui D
SAR QSAR Environ Res; 2010 Apr; 21(3-4):231-46. PubMed ID: 20544549
[TBL] [Abstract][Full Text] [Related]
20. Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.
Freitas RF; Galembeck SE
J Phys Chem B; 2006 Oct; 110(42):21287-98. PubMed ID: 17048958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
